<DOC>
	<DOCNO>NCT00869024</DOCNO>
	<brief_summary>The purpose study determine delivery cell implantation leave ventricular assist device help improve pump function heart minimize heart enlargement future . The cell obtain aspiration withdrawal fluid bone marrow pelvic bone use needle syringe . This would take place 24-48 hour prior plan leave ventricular assist device implantation . During surgery surgeon inject prepared cell take bone marrow inject heart muscle . This study test whether receive bone marrow cell directly heart help heart recover function placement leave ventricular assist device .</brief_summary>
	<brief_title>Stem Cell Therapy Patients With Severe Heart Failure &amp; Undergoing Left Ventricular Assist Device Placement</brief_title>
	<detailed_description>Patients meet inclusion exclusion criterion agree participate enrol study . All patient baseline EKG , Laboratory test , 2D ECHO PET/CT imaging.Day prior LVAD implantation patient undergo bone marrow aspiration . Bone marrow aspirate process accord protocol use facility . After processing , bone marrow mononuclear cell suspend 2ml 5 % human serum albumin label per standard protocol facility . Patients randomize 2:1 fashion either receive cell 5 % serum albumin . Under general anesthesia use standard technique HeartMate II ( LVAD ) place . The LVAD insert LV apex ( removal 2 x 2 cm ventricular core ) . The tissue core process RNA isolation morphological analysis . CV surgeon inject either cell placebo directly myocardium LAD territory . Ten separate injection deliver LV free wall ( 20 X 106 cell / 400 micro lit ) . The injection sit marked Titanium surgical clip . Subjects manage time current standard care hospital patient LVAD . Routine postoperative care procedure follow close follow-up dysrrhythmias sign infection . Tissue sample core leave ventricular apex remove time implantation LVAD compare myocardium ( marked surgical clip ) explanted heart time transplantation . These sample experimental subject control heart examine morphology interstitial fibrosis , hypertrophy , myocyte diameter myocytolysis well gene expression use RT-PCR . Research-related follow-up take place week 2 , 4 , 6 , 8 month 6 , 12 , 18 24 LVAD implant Clinical Trial Center Cardiology Division University Minnesota . Patients examine PI Sub-I visit . Follow data obtain clinic visit outline protocol</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Severe LV dysfunction EF &lt; 30 % cardiomyopathy ( Ischemic non ischemic ) 2 . NYHA Class III IV 3 . No revascularization option available 4 . LVAD placement destination therapy bridge transplantation 5 . Age 1880 year 1 . History recent malignancy ( less one year ) . 2 . Unstable hemodynamics time implant ; define need increase vasopressor medication last 24 hour blood pressure &lt; 70 systolic , cardiac index &lt; 1.3 liters/min . 3 . Coronary anatomy suitable revascularization time surgery 4 . Pregnancy confirm positive urine test 5 . Lactating mother 6 . Renal failure serum creatinine &gt; 3.0 , receive chronic dialysis support . 7 . Inability undergo PET/CT imaging . 8 . A history significant recent bleed disorder coagulation profile concern acute bleeding , INR &gt; 2.0 ( anticoagulant ) , platelet count &lt; 100,000 , hemoglobin &lt; 8.0 gr/dl . 9 . Patients know infectious disease ( Hepatitis , HIV ) etc . 10 . Patients three time upper limit normal enzyme .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>Left ventricular assist device</keyword>
	<keyword>Stem cell</keyword>
</DOC>